Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 8/2018

01-08-2018 | Systematic Review

Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations

Authors: R. Brett McQueen, Danielle N. Sheehan, Melanie D. Whittington, Job F. M. van Boven, Jonathan D. Campbell

Published in: PharmacoEconomics | Issue 8/2018

Login to get access

Abstract

Background

Recently developed asthma biological therapies have been shown to provide relief for severe asthma patients not controlled by inhaled treatment. Given the relatively high costs of biological therapies, cost-effectiveness analyses (CEAs) may be required as a prerequisite for coverage and reimbursement.

Objective

We aimed to systematically review published literature on the economic impact of biological asthma therapies and to identify key drivers that impact cost-effectiveness in order to provide recommendations for future economic evaluations.

Methods

We conducted a systematic literature search in PubMed and Google Scholar. We included studies that assessed the cost-effectiveness of asthma biologics and were published in English between 2000 and 2018. The Quality of Health Economic Studies (QHES) instrument was used to evaluate quality.

Results

Twenty asthma biological CEAs were identified. Nineteen studies analyzed the cost-effectiveness of omalizumab, and one study analyzed mepolizumab. Ten studies concluded that omalizumab was cost-effective in base-case scenarios, four studies concluded omalizumab was not cost-effective, and the remaining studies concluded omalizumab or mepolizumab was cost-effective only when targeted to specific severe subgroups or given considerable price discounts. Key drivers of cost-effectiveness included day-to-day health-related quality of life (HRQoL), asthma-related mortality, acquisition price of the biological therapy, and time horizon.

Conclusions

Most studies recommended carefully targeting biological therapy to specific populations such as responders or discounting acquisition price in order to further improve value. The quality of the studies was generally satisfactory, but improved evidence is needed linking HRQoL to utilities as well as understanding interventions’ impact on asthma-related mortality. Key recommendations from this review may allow for greater comparability across future cost-effectiveness studies.
Appendix
Available only for authorised users
Literature
1.
O’Toole J, Mikulic L, Kaminsky DA. Epidemiology and pulmonary physiology of severe asthma. Immunol Allergy Clin. 2016;36(3):425–38.CrossRef
2.
To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;19(12):204.CrossRef
3.
Sullivan S, Rasouliyan L, Russo P, Kamath T, Chipps B. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy. 2007;62(2):126–33.PubMedCrossRef
4.
Sullivan PW, Ghushchyan VH, Campbell JD, Globe G, Bender B, Magid DJ. Measuring the cost of poor asthma control and exacerbations. J Asthma. 2017;54(1):24–31.PubMedCrossRef
5.
6.
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–84.PubMedPubMedCentralCrossRef
7.
Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–16.PubMedCrossRef
8.
Darveaux J, Busse WW. Biologics in asthma–the next step toward personalized treatment. J Allergy Clin Immunol Pract. 2015;3(2):152–60 (quiz 61).
9.
10.
11.
12.
13.
Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract. 2017;5(2):S1–14.PubMedCrossRef
14.
15.
16.
17.
18.
Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database of Systematic Reviews. 2017(9).
19.
20.
21.
Akinbami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert TV, Lee TA, et al. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol. 2012;129(3 Suppl):S49–64.PubMedPubMedCentralCrossRef
22.
Ofman JJ, Sullivan SD, Neumann PJ, Chiou C-F, Henning JM, Wade SW, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53–61.PubMed
23.
24.
25.
26.
27.
Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2013;17(52):1–342.
28.
Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–5.PubMedCrossRef
29.
Faria R, McKenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. Value Health. 2014;17(8):772–82.PubMedCrossRef
30.
31.
Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, et al. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 years: a NICE single technology appraisal. PharmacoEconomics. 2012;30(11):991–1004.PubMedCrossRef
32.
Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy. 2007;62(2):149–53.PubMedCrossRef
33.
Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy. 2010;65(9):1141–8.PubMed
34.
Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol. 2011;43(2):45–53.
35.
Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma. 2012;49(8):843–8.CrossRef
36.
Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22(9):1765–76.PubMedCrossRef
37.
Levy AN, Garcia ARAJ, Garcia-Agua Soler N, Sanjuan MV. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015;52(2):205–10.PubMedCrossRef
38.
Menzella F, Facciolongo N, Piro R, Formisano D, Roggeri A, Simonazzi A, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Therapeut Adv Respir Dis. 2012;6(2):87–95.CrossRef
39.
Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial. Value Health Reg Issues. 2013;2(1):29–36.
40.
Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2004;114(2):265–9.PubMedCrossRef
41.
Suzuki C, Lopes da Silva N, Kumar P, Pathak P, Ong SH. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. J Med Econ. 2017;20(8):832–9.PubMedCrossRef
42.
van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ. 2013;16(3):342–8.PubMedCrossRef
43.
Vennera Mdel C, Valero A, Uria E, Forne C, Picado C. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567–78.PubMedCrossRef
44.
Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol. 2007;120(5):1146–52.PubMedPubMedCentralCrossRef
45.
Yoshikawa H, Iwata M, Matsuzaki H, Ono R, Murakami Y, Taba N, et al. Impact of omalizumab on medical cost of childhood asthma in Japan. Pediatr Int. 2016;58(5):425–8.PubMedCrossRef
46.
Zafari Z, Sadatsafavi M, Marra CA, Chen W, FitzGerald JM. Cost-effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma. PLoS One. 2016;11(1):e0146003.PubMedPubMedCentralCrossRef
47.
Zafari Z, Sadatsafavi M, FitzGerald JM. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Effect Resour Alloc. 2018;16(1):3.CrossRef
48.
49.
Bousquet J, Siergiejko Z, Świebocka E, Humbert M, Rabe K, Smith N, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66(5):671–8.PubMedCrossRef
50.
Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. A comparison of the responsiveness of different generic health status measures in patients with asthma. Qual Life Res. 2003;12(5):555–63.PubMedCrossRef
51.
Campbell JD, McQueen RB, Briggs A. The, “e” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Ann Am Thorac Soc. 2014;11(Suppl 2):S105–11.PubMedCrossRef
52.
Dekhuijzen R, Lavorini F, Usmani OS, van Boven JF. Addressing the impact and unmet needs of nonadherence in asthma and chronic obstructive pulmonary disease: where do we go from here? J Allergy Clin Immunol Pract. 2018.
53.
Price DB, Roman-Rodriguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5(4):1071–81.e9.
54.
Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am. 2010;43(4):753–68.PubMedCrossRef
55.
Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413–32.PubMedCrossRef
56.
Sweeney J, Patterson CC, Menzies-Gow A, Niven RM, Mansur AH, Bucknall C, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71(4):339–46.PubMedCrossRef
57.
Zazzali JL, Broder MS, Omachi TA, Chang E, Sun GH, Raimundo K. Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. Allergy Asthma Proc. 2015;36(4):268–74.
58.
59.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.PubMedCrossRef
60.
Gold M. Panel on cost-effectiveness in health and medicine. Med Care. 1996;34(12):DS197–DS9.
61.
Braunstahl G-J, Chen C-W, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–51.PubMedCrossRef
62.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. PharmacoEconomics. 2013;31(5):361–7.PubMedCrossRef
63.
Garrison LP Jr, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, et al. A health economics approach to us value assessment frameworks-summary and recommendations of the ISPOR special task force report [7]. Value Health. 2018;21(2):161–5.PubMedCrossRef
64.
Sulaiman I, Greene G, MacHale E, Seheult J, Mokoka M, D’Arcy S, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J. 2018;51(1):1701126.PubMedCrossRef
65.
van Boven JF, Ryan D, Eakin MN, Canonica GW, Barot A, Foster JM. Enhancing respiratory medication adherence: the role of health care professionals and cost-effectiveness considerations. J Allergy Clin Immunol Pract. 2016;4(5):835–46.PubMedCrossRef
Metadata
Title
Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations
Authors
R. Brett McQueen
Danielle N. Sheehan
Melanie D. Whittington
Job F. M. van Boven
Jonathan D. Campbell
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2018
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-018-0658-x

Other articles of this Issue 8/2018

PharmacoEconomics 8/2018 Go to the issue

Practical Application

Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial

Original Research Article

Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors

Original Research Article

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

Letter to the Editor

Comment on: “Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales Onto the Child Health Utility Index-9 Dimension (CHU-9D) Score for Economic Evaluation in Children”

Commentary

Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation

Systematic Review

Does Non-Adherence Increase Treatment Costs in Schizophrenia?